Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: GlobeNewswire
PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, supports Lewy Body Dementia Awareness Month and the critical need for more attention, research, and treatments for people with dementia with Lewy bodies (DLB). DLB is the second most common form of progressive dementia, affecting approximately 1.4 million people in the U.S., with no approved treatments available. DLB is caused by the buildup of a protein called alpha-synuclein, which forms deposits called Lewy bodies inside neurons. Over time, these deposits interfere with normal cellular functions, causing a progressive decline in cognitive and motor skills. Symptoms of DLB vary among patients and fluctuate in intensity, making it challenging to diagnose and manage. These symptoms include impaired cognition and mental organization, visual hallucinations, REM sleep behavior di
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.MarketBeat
- Life Sciences Investor Forum: Presentations Now Available for Online ViewingGlobeNewswire
- Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical UpdateGlobeNewswire
- Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor ForumGlobeNewswire
- Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
CGTX
Earnings
- 11/13/24 - Miss
CGTX
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- 10/1/24 - Form 8-K
- CGTX's page on the SEC website